Mithra - Publication of a transparency notification received from Scorpiaux BV
05 Giugno 2023 - 5:45PM
Mithra - Publication of a transparency notification received from
Scorpiaux BV
Publication of a transparency notification
received from Scorpiaux BV
Liege,
Belgium,
05 June
2023
–
17:45
CEST – Mithra
(Euronext Brussels: MITRA), a company dedicated to Women’s Health,
today announces, in accordance with Article 14 of the Belgian Law
of 2 May 2007 regarding the publication of major shareholdings in
issuers whose securities are admitted to trading on a regulated
market (the “Transparency Law”), that it received a notification of
transparency from Scorpiaux BV, with registered offices at
Blinckaertlaan 4, 8300 Knokke-Heist, on 31, May 2023.
Scorpiaux BV notified Mithra that it has
passively fallen below the statutory 3% threshold on 14 March 2023.
Scorpiaux BV now holds 2.88% (1,641,407 shares) of the 57,073,622
shares currently outstanding.
The detailed transparency notifications are
available on the Investors section of Mithra
(mithra.com/en/investors/). An updated overview of the Mithra’s
shareholders structure will be included in the corporate governance
charter of Mithra, which will be made available on its website.
********
For more information, please
contact:
Investor relations
: investorrelations@mithra.com
About
Mithra
Mithra (Euronext: MITRA) is a Belgian biotech
company dedicated to transforming Women’s Health by offering new
choices through innovation, with a particular focus on
contraception and menopause. Mithra’s goal is to develop products
offering better efficacy, safety and convenience, meeting women’s
needs throughout their life span. Mithra explores the potential of
the unique native estrogen estetrol in a wide range of applications
in women health and beyond. After having successfully launched the
first estetrol-based product in 2021, the contraceptive pill
Estelle®, Mithra is now focusing on its second product Donesta®,
the next-generation hormone therapy. Mithra also offers partners a
complete spectrum of solutions from early drug development,
clinical batches and commercial manufacturing of complex polymeric
products (vaginal ring, implants) and complex liquid injectables
and biologicals (vials, pre-filled syringes or cartridges) at its
technological platform Mithra CDMO. Active in more than 100
countries around the world, Mithra - is headquartered in Liège,
Belgium. www.mithra.com
ESTELLE®, DONESTA® are registered trademarks of
Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
Subscribe to our mailing list on mithra.com to receive our press
releases by email or follow us on our social media :LinkedIn •
Twitter • Facebook |
- 2023-06-02_Mithra_Press-release_Transparency_Notification
_FR
Grafico Azioni Mithra Pharmaceuticals (EU:MITRA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Mithra Pharmaceuticals (EU:MITRA)
Storico
Da Giu 2023 a Giu 2024